Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trialKwee Yong, Rakesh Popat, William Wilson et al.|The Lancet Haematology|2022Cited by 25
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Kwee Yong, Jonathan Sive et al.|British Journal of Haematology|2021Cited by 15
Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).Kwee Yong, Rakesh Popat, Marquita Camilleri et al.|Journal of Clinical Oncology|2021Cited by 5
Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signatureIeuan Walker, Michael A. Chapman, Venetia D’arcy et al.|medRxiv|2023Cited by 2
OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)Rakesh Popat, Kwee Yong, William Wilson et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1